Use of L-carnitine for the manufacture of a medicament for the treatment of toxic effects induced by the inhalation of halothane and other halogen-containing general anesthetics.

摘要

Oral or parenteral administration of 10 to 30 mg/Kg/day of L-carnitine (or an equivalent amount of a pharmacologically acceptable salt thereof) both during preanesthesia and post-operative phase antagonizes the toxic effects (particularly on kidneys and liver) induced by inhalation of halogen-containing general anesthetics such as, typically, halotane.